Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin)

Vox Sanguinis
Peter SchellongowskiPaul Knöbl

Abstract

The aim of this study was to document the effects of supplementation with a plasma-derived protein C concentrate in adult patients with infectious purpura fulminans. We report the effect of the administration of a human protein C concentrate (Ceprotin, Baxter, Vienna, Austria) in eight adult patients with purpura fulminans. Five patients received the concentrate as level-adjusted continuous infusion (10 U/kg/h, target protein C activity 100%) and three patients received the concentrate as bolus infusions (100 U/kg every 6 h) in addition to standard sepsis therapy. Heparin, fresh-frozen plasma, antithrombin- and fibrinogen concentrates, low-dose rtPA, and platelet transfusions were given when appropriate. Six patients had overt disseminated intravascular coagulation: platelets, 19 g/l; fibrinogen, 60 mg/dl; antithrombin, 47%; prothrombin time, 32%; activated partial thromboplastin time (APTT), 88 s; d-dimer, 66 microg/ml; protein C activity, 29% (medians). Five patients had septic shock, six renal failure and four respiratory failure. Patients received between 5000 and 77,000 U of protein C concentrate over 2.5 days (median); the protein C activity increased to 184% (median) and coagulopathy resolved within 3 days in seven of th...Continue Reading

References

Jul 4, 1987·Lancet·J F SinclairD Hallworth
Apr 1, 1995·The Journal of Pediatrics·G E RivardH P Schwarz
Jan 1, 1997·European Journal of Clinical Investigation·M LeviS J van Deventer
May 20, 1998·Critical Care Medicine·E RintalaV Rasi
Aug 19, 1999·The New England Journal of Medicine·M Levi, H Ten Cate
Jun 29, 2000·Intensive Care Medicine·R C ClarkeE E Mayne
Aug 2, 2000·Critical Care Medicine·E RintalaP Kotilainen
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Jan 17, 2002·The New England Journal of Medicine·G van den BergheR Bouillon
Jan 17, 2002·The New England Journal of Medicine·E RiversUNKNOWN Early Goal-Directed Therapy Collaborative Group
Aug 21, 2002·JAMA : the Journal of the American Medical Association·Djillali AnnaneEric Bellissant

❮ Previous
Next ❯

Citations

May 7, 2008·Intensive Care Medicine·Fabio BarattoCarlo Ori
Apr 7, 2010·Wiener medizinische Wochenschrift·Paul Knoebl
Sep 21, 2007·Current Infectious Disease Reports·Herwig Gerlach, Susanne Toussaint
Oct 29, 2014·Medizinische Klinik, Intensivmedizin und Notfallmedizin·F M Brunkhorst, V Patchev
Dec 17, 2008·Clinical and Experimental Dermatology·L NguM Davies
Oct 21, 2016·Intensive Care Medicine·Federico PappalardoAlberto Zangrillo
Dec 17, 2009·Clinical Orthopaedics and Related Research·Savyasachi C ThakkarSimon C Mears
Jul 17, 2009·Acta Paediatrica·Doris FischerAlex Veldman
Jan 31, 2009·Revista española de anestesiología y reanimación·U SalinasL Aguilera
Aug 6, 2013·American Journal of Physiology. Lung Cellular and Molecular Physiology·Sarah C ChristiaansJean Francois Pittet
Nov 28, 2013·Pediatric Blood & Cancer·Francesco De LeonardisNicola Santoro
Dec 14, 2011·Thrombosis Research·Patrizia Della ValleArmando D'Angelo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.